Biome Australia (ASX: BIO) edged close to breakeven in FY26, driven by $1.8 million in international sales across four markets and a 68% gross margin. The company is set to launch onshore manufacturing and a digital health platform to accelerate growth.
- FY26 international revenue reached $1.8 million, nearly covering operating expenses
- International gross margin hit 68%, 7 percentage points above domestic levels
- Onshore manufacturing in Australia to start September 2026, improving supply chain and margins
- Digital B2B2C and e-script platform launching in H1 FY27, starting in the UK
- Four international markets contributing with 2,000 distribution points and 12 FTE
International Expansion Approaches Profitability
Biome Australia (ASX:BIO) is closing in on breakeven in its international operations after FY26 revenue of $1.8 million almost matched its $1.82 million operating expenses. The company’s four active markets; Canada, the UK, Ireland, and New Zealand; delivered a blended gross margin of approximately 68%, notably 7 percentage points higher than its domestic margin. This premium margin reflects a practitioner-led, non-discounted sales model that Biome has successfully replicated from its Australian base.
Australian Model Driving Global Growth
Biome’s international strategy leans heavily on the proven Australian approach, where the company scaled from 100 to 7,500 pharmacy points of sale over six years. Its flagship product, Biome Daily Probiotic, holds the number one position in Australian pharmacies, a feat it aims to mirror overseas. In FY26, same-store sales in Australia grew 38.6%, with 1,600 new accounts added, setting a steep growth curve for international markets still in their early stages.
Market-Specific Strategies and Partnerships
Each international market has a tailored approach. In Canada, Biome deepened distribution with five partners spanning practitioner, pharmacy, and health-food channels, anchored by platforms such as Fullscript and Ecotrend. The UK serves as the Northern Hemisphere hub, managing sales, marketing, and distribution for the EU and Canada, with plans to test a direct-to-practitioner e-script portal in H1 FY27. Ireland’s strategy combines pharmacy banner expansion with GP and dentist engagement, while New Zealand focuses on practitioner base growth and a pharmacy launch through ProPharma and Green Cross.
Onshore Manufacturing to Boost Margins and Supply
Starting September 2026, Biome will produce its Activated Probiotics onshore through Specialty Probiotics Australia (SPA), a move anticipated to reduce costs, improve product quality, and shorten supply lead times. This shift to local small-batch manufacturing supports market-specific packaging needs and aligns with the brand’s premium, practitioner-only positioning. While no quantified guidance was provided, the company expects this step change to underpin future margin expansion.
Digital Innovation with B2B2C and E-Script Portal
In a bid to deepen its practitioner-led model, Biome plans to launch a B2B2C digital health platform and e-script portal in the UK during H1 FY27. This initiative allows healthcare practitioners to prescribe Biome products directly, with orders fulfilled by Biome, maintaining tight control over brand integrity and capturing margin and demand data at the source. The UK launch will serve as a testbed before a global rollout.
FY27 Priorities and Future Market Reviews
With 12 international full-time employees and roughly 2,000 distribution points established, Biome’s FY27 priorities include unlocking the Quebec market, expanding Canadian pharmacy chains, converting UK pharmacy banners, and growing pharmacy presence in Ireland. The company also maintains a disciplined approach to new markets, requiring practitioner-led entry, clinical evidence, and sound economics before committing to expansion.
Bottom Line?
Biome’s international platform is on the cusp of profitability, with manufacturing and digital innovations poised to accelerate its global footprint.
Questions in the middle?
- How quickly will onshore manufacturing translate into improved gross margins and cost efficiencies?
- Will the B2B2C e-script platform meaningfully deepen practitioner engagement and sales across markets?
- Which new international markets will meet Biome’s strict entry criteria beyond the current four?